Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

Objective To develop Canadian recommendations for the screening, monitoring, and treatment of uveitis associated with juvenile idiopathic arthritis (JIA). Methods Recommendations were developed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach. A working group of 14 pediatric rheumatologists, 6 ophthalmologists, 2 methodologists, and 3 caregiver/patient representatives reviewed recent American College of Rheumatology (ACR)/Arthritis Foundation (AF) recommendations and worked in pairs to develop evidence-to-decision (EtD) tables. A survey to assess agreement and recommendations requiring group discussion was completed. EtD tables were presented, discussed, and voted upon at a virtual meeting, to produce the final recommendations. A health equity framework was applied to all aspects of the adolopment process including the EtD tables, survey responses, and virtual meeting discussion. Results The survey identified that 7 of the 19 recommendations required rigorous discussion. Seventy-five percent of working group members attended the virtual meeting to discuss controversial topics as they pertained to the Canadian environment, including timing to first eye exam, frequency of screening, escalation criteria for systemic and biologic therapy, and the role of nonbiologic therapies. Equity issues related to access to care and advanced therapeutics across Canadian provinces and territories were highlighted. Following the virtual meeting, 5 recommendations were adapted, 2 recommendations were removed, and 1 was developed de novo. Conclusion Recommendations for JIA-associated uveitis were adapted to the Canadian context by a working group of pediatric rheumatologists, ophthalmologists with expertise in the management of uveitis, and parent/patient input, taking into consideration cost, equity, and access.

[1]  B. Feldman,et al.  Variations in Pediatric Rheumatology Workforce and Care Processes Across Canada , 2021, The Journal of Rheumatology.

[2]  C. Barnabe,et al.  Informing the Evidence to Decision Process with Health Equity Considerations: Demonstration from the Canadian Rheumatoid Arthritis Care Context. , 2021, Journal of clinical epidemiology.

[3]  C. Barnabe,et al.  Supporting Equity in Rheumatoid Arthritis Outcomes in Canada: Population-Specific Factors in Patient-Centered Care. , 2021, The Journal of rheumatology.

[4]  Justine R. Smith,et al.  Recommendations for the management of childhood juvenile idiopathic arthritis‐type chronic anterior uveitis , 2021, Clinical & experimental ophthalmology.

[5]  G. Bertelsen,et al.  Uveitis in Juvenile Idiopathic Arthritis: 18-year Outcome in the Population-based Nordic Cohort Study. , 2020, Ophthalmology.

[6]  D. Goldstein,et al.  Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease. , 2020, Ophthalmology.

[7]  P. Quartier Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis , 2020 .

[8]  Ashley P Jones,et al.  Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial , 2020, The Lancet Rheumatology.

[9]  K. Rahmani,et al.  Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis , 2020, Orphanet Journal of Rare Diseases.

[10]  R. Cimaz,et al.  JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis , 2020, Clinical Rheumatology.

[11]  R. Schneider,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis , 2019, Arthritis & rheumatology.

[12]  C. Foster,et al.  The Challenge of Pediatric Uveitis: Tertiary Referral Center Experience in the United States , 2019, Ocular immunology and inflammation.

[13]  Sheila T. Angeles-Han,et al.  Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis–Associated and Idiopathic Chronic Anterior Uveitis , 2019, Arthritis care & research.

[14]  B. Feldman,et al.  Prospective Determination of the Incidence and Risk Factors of New‐Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort , 2019, Arthritis care & research.

[15]  W. Armbrust,et al.  Efficacy of High-Dose Methotrexate in Pediatric Non-Infectious Uveitis , 2018, Ocular immunology and inflammation.

[16]  R. Cimaz,et al.  Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting , 2018, Pediatric Rheumatology.

[17]  M. González-Gay,et al.  Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. , 2018, Clinical and experimental rheumatology.

[18]  A. Heiligenhaus,et al.  Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative , 2018, Annals of the rheumatic diseases.

[19]  C. Elie,et al.  ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis , 2017, Annals of the rheumatic diseases.

[20]  G. Guyatt,et al.  [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines]. , 2018, Gaceta sanitaria.

[21]  R. Cafferty,et al.  Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis , 2018, Clinical Rheumatology.

[22]  M. Zetterberg,et al.  Assessment of the outcome of ophthalmological screening for uveitis in a cohort of Swedish children with juvenile idiopathic arthritis , 2017, Acta ophthalmologica.

[23]  T. Kivelä,et al.  Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. , 2017, Clinical and experimental rheumatology.

[24]  Ashley P Jones,et al.  Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis , 2017, The New England journal of medicine.

[25]  Alonso Carrasco-Labra,et al.  GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. , 2017, Journal of clinical epidemiology.

[26]  S. Calleja-Antolín,et al.  Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. , 2016, Ophthalmology.

[27]  R. Cimaz,et al.  Comparable Efficacy of Abatacept Used as First-line or Second-line Biological Agent for Severe Juvenile Idiopathic Arthritis-related Uveitis , 2016, The Journal of Rheumatology.

[28]  Anne‐Mieke J. W. Haasnoot,et al.  Impact of Juvenile Idiopathic Arthritis Associated Uveitis in Early Adulthood , 2016, PloS one.

[29]  O. Kalashnikova,et al.  Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. , 2016, Clinical and experimental rheumatology.

[30]  M. Zierhut,et al.  Mycophenolate sodium for the treatment of chronic non-infectious uveitis of childhood , 2015, British Journal of Ophthalmology.

[31]  I. Foeldvari,et al.  Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry , 2015, Arthritis care & research.

[32]  J. Kempen,et al.  The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. , 2015, Ophthalmology.

[33]  P. Meroni,et al.  Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis , 2015, British Journal of Ophthalmology.

[34]  W. Muntean,et al.  Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response , 2015, Scandinavian journal of rheumatology.

[35]  A. Heiligenhaus,et al.  Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis , 2015, The Journal of Rheumatology.

[36]  P. Meroni,et al.  Long-term Treatment with Golimumab for Severe Uveitis , 2014, Ocular immunology and inflammation.

[37]  Y. Buys,et al.  The landscape of ophthalmologists in Canada: present and future. , 2013, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[38]  P. Paudyal,et al.  Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. , 2013, Rheumatology.

[39]  E. Haddad,et al.  Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis , 2012, The Journal of Rheumatology.

[40]  R. V. Van Gelder,et al.  Efficacy and potential complications of difluprednate use for pediatric uveitis. , 2012, American journal of ophthalmology.

[41]  C. Foster,et al.  Mycophenolate mofetil monotherapy in the management of paediatric uveitis , 2011, Eye.

[42]  D. Jabs,et al.  Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. , 2010, Ophthalmology.

[43]  A. Heiligenhaus,et al.  Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis , 2010, British Journal of Ophthalmology.

[44]  R. Cimaz,et al.  Abatacept for severe anti–tumor necrosis factor α refractory juvenile idiopathic arthritis–related uveitis , 2010, Arthritis care & research.

[45]  R. Saurenmann,et al.  Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. , 2010, Arthritis and rheumatism.

[46]  J. G. Ryan,et al.  High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. , 2009, American journal of ophthalmology.

[47]  J. Chládek,et al.  Methotrexate bioavailability after oral and subcutaneous dministration in children with juvenile idiopathic arthritis. , 2009, Clinical and experimental rheumatology.

[48]  A. Heiligenhaus,et al.  Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis , 2009, Eye.

[49]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[50]  A. Rothova,et al.  Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic arthritis. , 2007, American journal of ophthalmology.

[51]  A. Heiligenhaus,et al.  Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. , 2007, Rheumatology.

[52]  A. Heiligenhaus,et al.  Methotrexate for uveitis associated with juvenile idiopathic arthritis : Value and requirement for additional anti-inflammatory medication , 2007 .

[53]  M. Zierhut,et al.  Mycophenolate mofetil in the treatment of uveitis in children , 2006, British Journal of Ophthalmology.

[54]  D. Levy,et al.  Favorable response to high-dose infliximab for refractory childhood uveitis. , 2006, Ophthalmology.

[55]  G. Ellis,et al.  Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. , 1999, Journal of pediatric ophthalmology and strabismus.

[56]  D. Mock,et al.  A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. , 1993, The Journal of rheumatology.

[57]  D. Musson,et al.  An in vitro comparison of the permeability of prednisolone, prednisolone sodium phosphate, and prednisolone acetate across the NZW rabbit cornea. , 1992, Journal of ocular pharmacology.